Given the recent development of novel small molecule PAR2 antagonists (Cheng et al. 2017; Kennedy et al. 2018), these will allow further characterisation of the role that PAR2 plays in CNS disorders, which in turn may highlight PAR2 as a target for the development of novel antidepressants. This evidence concerns the gene F2RL1 and central nervous system disorder.